BRAF V600E mutations are frequent in dysembryoplastic neuroepithelial tumors and subependymal giant cell astrocytomas

Journal of Surgical Oncology

Volumn 111, Issue 3, 2015, Pages 359-364

  Lee, Dakeun ^a   Cho, Young Hye ^b   Kang, So Young ^b   Yoon, Nara ^b   Sung, Chang Ohk ^c   Suh, Yeon Lim ^b  

^a Ajou University School of Medicine   (South Korea)

^b Sungkyunkwan University School of Medicine   (South Korea)

^c University of Ulsan College of Medicine   (South Korea)

Author keywords

BRAF; Dysembyoplastic neuroepithelial tumor; Glioblastoma with neuronal marker expression; Pleomorphic xanthoastrocytoma; Subependymal giant cell astrocytoma

Indexed keywords

BIOLOGICAL MARKER; THREONINE; B RAF KINASE; BRAF PROTEIN, HUMAN; DNA;

ADOLESCENT; ADULT; ARTICLE; BRAF GENE; CANCER GRADING; CANCER PATIENT; CHILD; CODON; DIFFERENTIAL DIAGNOSIS; DYSEMBRYOPLASTIC NEUROEPITHELIAL TUMOR; FEMALE; GENE DUPLICATION; GENE MUTATION; GENE SEQUENCE; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NEUROEPITHELIOMA; ONCOGENE; PLEOMORPHIC XANTHOASTROCYTOMA; PRIORITY JOURNAL; SUBEPENDYMAL GIANT CELL ASTROCYTOMA; TUMOR DIFFERENTIATION; AGED; ASTROCYTOMA; BRAIN TUMOR; FOLLOW UP; GENETICS; INFANT; MIDDLE AGED; MUTATION; PATHOLOGY; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; PROGNOSIS; TERATOMA; TUMOR RECURRENCE; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ASTROCYTOMA; BRAIN NEOPLASMS; CHILD; CHILD, PRESCHOOL; DNA, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFANT; MALE; MIDDLE AGED; MUTATION; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, NEUROEPITHELIAL; POLYMERASE CHAIN REACTION; PROGNOSIS; PROTO-ONCOGENE PROTEINS B-RAF; TERATOMA; YOUNG ADULT;

EID: 84921972778     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.23822     Document Type: Article

References (25)

1. Louis DN, Ohgaki H, Wiestler OK, et al.: editors. WHO Classification of tumours of the central nervous system. Lyon: IARC; 2007.
2. Daumas-Duport C, Scheithauer BW, Chodkiewicz JP, et al.: Dysembryoplastic neuroepithelial tumor: A surgically curable tumor of young patients with intractable partial seizures. Report of thirty-nine cases. Neurosurgery 1988;23:545-556.
3. Daumas-Duport C: Dysembryoplastic neuroepithelial tumours. Brain Pathol 1993;3:283-295.
4. Daumas-Duport C, Varlet P, Bacha S, et al.: Dysembryoplastic neuroepithelial tumors: Nonspecific histological forms-A study of 40 cases. J Neurooncol 1999;41:267-280.
5. Flaherty KT,McArthur G: BRAF, a target in melanoma: Implications for solid tumor drug development. Cancer 2010;116:4902-4913.
6. Peyssonnaux C, Eychene A: The Raf/MEK/ERK pathway: New concepts of activation. Biol Cell 2001;93:53-62.
7. Schindler G, Capper D, Meyer J, et al.: Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol 2011;121:397-405.
8. Dougherty MJ, Santi M, Brose MS, et al.: Activating mutations in BRAF characterize a spectrum of pediatric low-grade gliomas. Neuro Oncol 2010;12:621-630.
9. Chappe C, Padovani L, Scavarda D, et al.: Dysembryoplastic neuroepithelial tumors share with pleomorphic xanthoastrocytomas and gangliogliomas BRAF(V600E) mutation and xpression. Brain Pathol 2013;23:574-583.
10. Dimitriadis E, Alexiou GA, Tsotsou P, et al.: BRAF alterations in pediatric low grade gliomas and mixed neuronal-glial tumors. J Neurooncol 2013;113:353-358.
11. Sung CO, Suh YL, Hong SC: CD34 and microtubule-associated protein 2 expression in dysembryoplastic neuroepithelial tumours with an emphasis on dual expression in non-specific types. Histopathology 2011;59:308-317.
12. Northrup H, Krueger DA, International Tuberous Sclerosis Complex Consensus G: Tuberous sclerosis complex diagnostic criteria update: Recommendations of the 2012 international tuberous sclerosis complex consensus conference. Pediatr Neurol 2013;49:243-254.
13. Prabowo AS, Iyer AM, Veersema TJ, et al.: BRAF V600E mutation is associated with mTOR signaling activation in glioneuronal tumors. Brain Pathol 2014;24:52-66.
14. Lee D, Suh YL, Kang SY, et al.: IDH1 mutations in oligodendroglial tumors: Comparative analysis of direct sequencing, pyrosequencing, immunohistochemistry, nested PCR and PNA-mediated clamping PCR. Brain Pathol 2013;23:285-293.
15. Okamoto Y, Di Patre PL, Burkhard C, et al.: Population-based study on incidence, survival rates, and genetic alterations of low-grade diffuse astrocytomas and oligodendrogliomas. Acta Neuropathol 2004;108:49-56.
16. Astrinidis A, Henske EP: Tuberous sclerosis complex: Linking growth and energy signaling pathways with human disease. Oncogene 2005;24:7475-7481.
17. Koelsche C, Sahm F, Paulus W, et al.: BRAF V600E expression and distribution in desmoplastic infantile astrocytoma/ganglioglioma. Neuropathol Appl Neurobiol 2013.
18. Ozlen F, Gunduz A, Asan Z, et al.: Dysembryoplastic neuroepithelial tumors and gangliogliomas: Clinical results of 52 patients. Acta Neurochir (Wien) 2010;152:1661-1671.
19. Ray WZ, Blackburn SL, Casavilca-Zambrano S, et al.: Clinicopathologic features of recurrent dysembryoplastic neuroepithelial tumor and rare malignant transformation: A report of 5 cases and review of the literature. J Neurooncol 2009;94:283-292.
20. Rushing EJ, Thompson LD, Mena H: Malignant transformation of a dysembryoplastic neuroepithelial tumor after radiation and chemotherapy. Ann Diagn Pathol 2003;7:240-244.
21. Hammond RR, Duggal N, Woulfe JM, et al. Malignant transformation of a dysembryoplastic neuroepithelial tumor. Case report. J Neurosurg 2000;92:722-725.
22. Flaherty KT, Puzanov I, KimKB, et al.: Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010;363:809-819.
23. El-Osta H, Falchook G, Tsimberidou A, et al.: BRAF mutations in advanced cancers: Clinical characteristics and outcomes. PLoS ONE 2011;6:e25806.
24. Dias-Santagata D, Lam Q, Vernovsky K, et al.: BRAF V600E mutations are common in pleomorphic xanthoastrocytoma: Diagnostic and therapeutic implications. PLoS ONE 2011;6: e17948.
25. Gauchotte G, Philippe C, Lacomme S, et al.: BRAF, p53 and SOX2 in anaplastic thyroid carcinoma: Evidence for multistep carcinogenesis. Pathology 2011;43:447-452.